Opinion|Videos|January 2, 2025
Transurethral Resection and Cystectomy in Patients with NMIBC
Author(s)Mark D. Tyson II, M.D., M.P.H.
A panelist discusses how recent advances in transurethral resection of bladder tumor (TURBT) include enhanced visualization techniques like fluorescence-guided surgery and narrow-band imaging to improve tumor detection and complete resection, while radical cystectomy remains a critical option for high-risk NMIBC patients who fail conservative therapies.
Advertisement
- Please talk about utilization and advances in transurethral resection and cystectomy for patients with NMIBC.
Advertisement
Related to this article
The approval is supported by data from the phase 3 VOLGA trial.
enGene expects to initiate a BLA submission by the end of 2026.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
5